---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023902"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:28:28.856668+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q3 net income plummets to $0.2M on $116.9M revenue; cuts FY2022 guidance

## Summary
- Net revenue $116.9M (+3% YoY), but net income $0.2M vs $12.6M in Q3 2021.
- Adjusted EBITDA $11.6M, down 46% YoY; adjusted net income $5.1M, down 68%.
- FY2022 revenue guidance lowered to $448-465M, citing challenging physician office environment and reimbursement uncertainty.
- SG&A expenses surged 27% to $79.3M, pressuring margins.
- Cash $108M, debt $72.6M; no share repurchase or dividend changes.

## SEC filing metadata
- accession: 0000950170-22-023902
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000095017022023902/0000950170-22-023902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000095017022023902/orgo-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023902
- JSON: https://secwatch.observer/filing/0000950170-22-023902.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023902.txt

## Key facts
- Earnings Releases
  Organogenesis Holdings Inc. reported third quarter ended September 30, 2022 results: revenue $116.9 million, net income $0.2 million, EPS $0.00 per share. Guidance lowered.
  - Period: third quarter ended September 30, 2022
  - Revenue: $116.9 million
  - Net income: $0.2 million
  - EPS: $0.00 per share
  - Guidance: lowered
  - Result: reported results
  source text: & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results Summary: • Net revenue of $116.9 million for the third quarter of 2022, an increase of 3% compared to net revenue of $113.8 million for the third quarter of 2021. Net revenue for the third quarter of 2022 consists of: o
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661181/000095017022023902/0000950170-22-023902-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.